Our unique process, paired with innovation and continued improvement and evolution, puts us at the forefront.
Making a meaningful impact on patient care.
Humacyte CEO Dr. Laura Niklason Presents at J.P. Morgan Healthcare Conference
Oh, the Places Grads Go
Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient
Why Human Acellular Vessels (HAV)?
From lower costs to fewer operations, HAVs may offer critical benefits.
Our path to success.
With each year, we’ve moved closer to lifesaving treatments.